| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lakshmi N Yatham, Peter F Liddle, Vesna Sossi, Jonathan Erez, Nasim Vafai, Raymond W Lam, Stephan Blinde. Positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. Archives of general psychiatry. vol 69. issue 6. 2012-09-17. PMID:22664549. |
positron emission tomography study of the effects of tryptophan depletion on brain serotonin(2) receptors in subjects recently remitted from major depression. |
2012-09-17 |
2023-08-12 |
human |
| Fengfeng Ping, Jing Shang, Jia Zhou, Hongmei Zhang, Luyong Zhan. 5-HT(1A) receptor and apoptosis contribute to interferon-α-induced "depressive-like" behavior in mice. Neuroscience letters. vol 514. issue 2. 2012-09-14. PMID:22414862. |
recently, serotonin 1a (5-ht(1a)) receptor and cellular apoptosis are involved in mechanism(s) contributing to depression. |
2012-09-14 |
2023-08-12 |
mouse |
| YeeWen Candace Wu, Rachel A Hill, Maren Klug, Maarten van den Buus. Sex-specific and region-specific changes in BDNF-TrkB signalling in the hippocampus of 5-HT1A receptor and BDNF single and double mutant mice. Brain research. vol 1452. 2012-09-14. PMID:22464183. |
brain-derived neurotrophic factor (bdnf) and serotonin 5-ht1a receptors are implicated in the pathophysiology of depression and the mechanism of action of antidepressant drugs. |
2012-09-14 |
2023-08-12 |
mouse |
| N Dreimüller, A Tadić, A Dragicevic, K Boland, B Bondy, K Lieb, G Laux, W Maier, M J Müller, M L Rao, M Rietschel, J Röschke, P Zill, C Hiemk. The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depression. Pharmacopsychiatry. vol 45. issue 3. 2012-09-11. PMID:22086748. |
the serotonin transporter promoter polymorphism (5-httlpr) affects the relation between antidepressant serum concentrations and effectiveness in major depression. |
2012-09-11 |
2023-08-12 |
Not clear |
| Eberhard Fuchs, Gabriele Flügg. Cellular consequences of stress and depression. Dialogues in clinical neuroscience. vol 6. issue 2. 2012-09-10. PMID:22033809. |
antidepressants are presently believed to exert their primary biochemical effects by readjusting aberrant intrasynaptic concentrations of neurotransmitters, such as serotonin or noradrenaline, suggesting that imbalances viihin the monoaminergic systems contribute to the disorder (monoaminergic hypothesis of depression). |
2012-09-10 |
2023-08-12 |
Not clear |
| K Ranga R Krishna. Broken heart: depression in cardiovascular disease. Dialogues in clinical neuroscience. vol 5. issue 2. 2012-09-10. PMID:22034195. |
the recent sertraline antidepressant heart attack trial (sadhart) has shown that selective serotonin reuptake inhibitors like sertraline can be safely used in patients with depression following myocardial infarction. |
2012-09-10 |
2023-08-12 |
human |
| Francis Chaoulof. Neurogenetics of emotional reactivity to stress in animals. Dialogues in clinical neuroscience. vol 4. issue 4. 2012-09-10. PMID:22034202. |
we then examined human results indicating that allelic variations in the serotonin transporter (5-htt) may play a role in the etiology of neuroticism and depression. |
2012-09-10 |
2023-08-12 |
mouse |
| Humberto Corrêa, Marco Aurélio Romano-Silva, Fabrice Duval, Ana Carolina Campi-Azevedo, Vivtor Lima, Jean-Paul Mache. Research on serotonin and suicidal behavior: neuroendocrine and molecular approaches. Dialogues in clinical neuroscience. vol 4. issue 4. 2012-09-10. PMID:22034390. |
we then examined the association en the serotonin (5-hydroxytryptamine) receptor 5-ht(2a) gene polymorphism (t102c) and suicide in a sample of brazilian psychiatric inpatients (95 with schizophrenia, 78 with major depression) and 52 healthy controls. |
2012-09-10 |
2023-08-12 |
Not clear |
| Dana L McMakin, Thomas M Olino, Giovanna Porta, Laura J Dietz, Graham Emslie, Gregory Clarke, Karen Dineen Wagner, Joan R Asarnow, Neal D Ryan, Boris Birmaher, Wael Shamseddeen, Taryn Mayes, Betsy Kennard, Anthony Spirito, Martin Keller, Frances L Lynch, John F Dickerson, David A Bren. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. Journal of the American Academy of Child and Adolescent Psychiatry. vol 51. issue 4. 2012-08-31. PMID:22449646. |
anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. |
2012-08-31 |
2023-08-12 |
Not clear |
| Dana L McMakin, Thomas M Olino, Giovanna Porta, Laura J Dietz, Graham Emslie, Gregory Clarke, Karen Dineen Wagner, Joan R Asarnow, Neal D Ryan, Boris Birmaher, Wael Shamseddeen, Taryn Mayes, Betsy Kennard, Anthony Spirito, Martin Keller, Frances L Lynch, John F Dickerson, David A Bren. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. Journal of the American Academy of Child and Adolescent Psychiatry. vol 51. issue 4. 2012-08-31. PMID:22449646. |
to identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (ssri) treatment-resistant adolescents undergoing second-step treatment. |
2012-08-31 |
2023-08-12 |
Not clear |
| Joel Raskin, Thomas George, Renee E Granger, Nadia Hussain, George Weizhong Zhao, Lauren B Marangel. Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. Journal of psychiatric research. vol 46. issue 5. 2012-08-29. PMID:22410206. |
this multicenter, double-blind, randomized study investigated whether switching from a selective serotonin reuptake inhibitor (ssri) to a serotonin-norepinephrine reuptake inhibitor (snri), compared with switching to another ssri, improved apathy symptoms in patients who had been treated with a ssri for mdd for ≥ 3 months, were no longer depressed (montgomery-Åsberg depression rating scale [madrs] total score ≤ 15), and continued to have apathy (apathy evaluation scale--clinician rated version [aes-c] total score >30). |
2012-08-29 |
2023-08-12 |
Not clear |
| Feng Zhang, Hui Zhou, Belinda C Wilson, Jing-Shan Shi, Jau-Shyong Hong, Hui-Ming Ga. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism & related disorders. vol 18 Suppl 1. 2012-08-27. PMID:22166439. |
fluoxetine, a selective serotonin reuptake inhibitor, is commonly used for the treatment of major depression due to its tolerability and safety profiles. |
2012-08-27 |
2023-08-12 |
rat |
| Ioannis Paraskevaidis, John Palios, John Parissis, Gerasimos Filippatos, Maria Anastasiou-Nan. Treating depression in coronary artery disease and chronic heart failure: what's new in using selective serotonin re-uptake inhibitors? Cardiovascular & hematological agents in medicinal chemistry. vol 10. issue 2. 2012-08-27. PMID:22471956. |
treating depression in coronary artery disease and chronic heart failure: what's new in using selective serotonin re-uptake inhibitors? |
2012-08-27 |
2023-08-12 |
Not clear |
| Ioannis Paraskevaidis, John Palios, John Parissis, Gerasimos Filippatos, Maria Anastasiou-Nan. Treating depression in coronary artery disease and chronic heart failure: what's new in using selective serotonin re-uptake inhibitors? Cardiovascular & hematological agents in medicinal chemistry. vol 10. issue 2. 2012-08-27. PMID:22471956. |
novel treatment modalities such as selective serotonin re-uptake inhibitors (ssris) may improve depressive symptoms and prognosis of post-myocardial infarction and heart failure patients interacting with the common pathophysiological mechanisms of depression and cardiovascular disease. |
2012-08-27 |
2023-08-12 |
Not clear |
| Heidemarie Abrahamian, Peter Hofmann, Johann Kinzl, Hermann Topla. Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group). Neuropsychiatric disease and treatment. vol 8. 2012-08-27. PMID:22923994. |
in an earlier pilot study, we found that treatment with the serotonin norepinephrine reuptake inhibitor antidepressant, milnacipran, significantly improved metabolic parameters in diabetic patients with comorbid depression who had an antidepressant response. |
2012-08-27 |
2023-08-12 |
Not clear |
| Boadie W Dunlop, Paula G Davi. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Primary care companion to the Journal of clinical psychiatry. vol 10. issue 3. 2012-08-23. PMID:18615162. |
to review the literature on the co-occurrence of anxiety with depressive disorders and the rationale for and use of combination treatment with benzodiazepines and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors (ssris/snris) for treating comorbid anxiety and depression. |
2012-08-23 |
2023-08-12 |
Not clear |
| Darakhshan Jabeen Halee. Raphe-Hippocampal Serotonin Neurotransmission In The Sex Related Differences of Adaptation to Stress: Focus on Serotonin-1A Receptor. Current neuropharmacology. vol 9. issue 3. 2012-08-23. PMID:22379463. |
a decrease in the function of 5-hydroxytryptamine (5-ht; serotonin) in the hippocampus and an increased function of the 5-ht-1a receptor in the raphe nucleus coexist in depression. |
2012-08-23 |
2023-08-12 |
Not clear |
| Darakhshan Jabeen Halee. Raphe-Hippocampal Serotonin Neurotransmission In The Sex Related Differences of Adaptation to Stress: Focus on Serotonin-1A Receptor. Current neuropharmacology. vol 9. issue 3. 2012-08-23. PMID:22379463. |
the present article reviews research on sex related differences of raphe-hippocampal serotonin neurotransmission to find a possible answer that may account for the sex differences of adaptation to stress reported in preclinical research and greater incidence of depression in women than men. |
2012-08-23 |
2023-08-12 |
Not clear |
| Mauricio Schüler Nin, Luis A Martinez, Fabio Pibiri, Marianela Nelson, Graziano Pinn. Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression. Frontiers in endocrinology. vol 2. 2012-08-23. PMID:22649384. |
the pharmacological action of selective serotonin reuptake inhibitor antidepressants may include a normalization of the decreased brain levels of the brain-derived neurotrophic factor (bdnf) and of neurosteroids such as the progesterone metabolite allopregnanolone, which are decreased in patients with depression and posttraumatic stress disorders (ptsd). |
2012-08-23 |
2023-08-12 |
mouse |
| Edward C Lauterbac. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Medical hypotheses. vol 78. issue 6. 2012-08-22. PMID:22401777. |
treatment-refractory depression properties include increased serotonin and norepinephrine availability, pcp, nmdr-2b, presynaptic alpha-2 antagonism, and the multiplicity of other antidepressant receptor mechanisms. |
2012-08-22 |
2023-08-12 |
Not clear |